4.7 Article

The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+ T-cell immunity

期刊

CELLULAR & MOLECULAR IMMUNOLOGY
卷 -, 期 -, 页码 -

出版社

CHIN SOCIETY IMMUNOLOGY
DOI: 10.1038/s41423-023-01093-y

关键词

Antitumor immunity; CD8(+) T cell; T-cell-based immunotherapy; TRAF6; CTLA-4

向作者/读者索取更多资源

This study reveals the regulatory mechanism of CTLA-4 stability mediated by TNF receptor-associated factor 6 (TRAF6) and suggests its functional significance in CD8(+) T-cell-mediated antitumor immunity. Additionally, the OX40-TRAF6 axis is found to be responsible for CTLA-4 degradation, thus controlling antitumor immunity in both tumor-bearing mice and patients with cancer. These findings highlight the potential of targeting the OX40-TRAF6 axis to improve T-cell-based immunotherapies.
Immune checkpoint blockade (ICB), including anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4), benefits only a limited number of patients with cancer. Understanding the in-depth regulatory mechanism of CTLA-4 protein stability and its functional significance may help identify ICB resistance mechanisms and assist in the development of novel immunotherapeutic modalities to improve ICB efficacy. Here, we identified that TNF receptor-associated factor 6 (TRAF6) mediates Lys63-linked ubiquitination and subsequent lysosomal degradation of CTLA-4. Moreover, by using TRAF6-deficient mice and retroviral overexpression experiments, we demonstrated that TRAF6 promotes CTLA-4 degradation in a T-cell-intrinsic manner, which is dependent on the RING domain of TRAF6. This intrinsic regulatory mechanism contributes to CD8(+) T-cell-mediated antitumor immunity in vivo. Additionally, by using an OX40 agonist, we demonstrated that the OX40-TRAF6 axis is responsible for CTLA-4 degradation, thereby controlling antitumor immunity in both tumor-bearing mice and patients with cancer. Overall, our findings demonstrate that the OX40-TRAF6 axis promotes CTLA-4 degradation and is a potential therapeutic target for the improvement of T-cell-based immunotherapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据